NAVLIN Daily NewsCheckout Today’s News
Germany's Federal Cabinet has adopted the draft bill to stabilize the contribution rates in the statutory health insurance (GKV) from 2027The draft will now be debated and negotiated in the Bundestag, the lower house of the parliament, before being finalizedFederal Chancellor Friedrich Merz, stated in a post on X “We can't just continue as we have done for the last 20 years. We have to show that we can change. Health, long-term care and pension insurance are three major reform projects. We hope that this will lead to more confidence”
Last week, NAVLIN Daily brought you key market access developments from across the globe. We highlighted new details of Germany’s GKV reform bill, showing the government is moving ahead with cost-containment measures, while AstraZeneca warned the proposals could delay future medicine launches in the countryThe EU’s NCAPR warned that U.S. MFN drug pricing could shift financial pressure onto European health systemsMeanwhile, U.S. Senate Democrats introduced a bill requiring HHS to make public the terms of MFN drug pricing deals with pharmaceutical companies
Spain’s Health Minister, Mónica García has underscored during a Senate meeting that the work on the royal decree on the evaluation of health technologies will be finalized in the coming weeks“We need the process of assessing the introduction of new health technologies into our healthcare system to be fully effective and efficient, and to be backed by robust scientific evidence, so that we can offer our patients the best possible guarantees,” stated GarcíaEarlier this week, Secretary of State for Health Javier Padilla confirmed that the draft had been passed with amendments by the Council of State
Speaking at this year’s Association of the British Pharmaceutical Industry's (ABPI) annual meeting in London, Dr Richard Torbett, Chief Executive of the group, argued that both the UK pharmaceutical industry and the global market are “undergoing one of the most profound shifts in a generation”Despite pointing to the hopeful tone of the ongoing themes of the ABPI meetings: “Health, growth, and renewal,” Torbett suggested “this year feels different to me,” adding that “Europe has significantly lost its global share in R&D investment, but we've lost even more of that share, and we've lost it faster, in the UK” He pointed to the U.S.’ Most Favored Nation (MFN) policy as a catalyst for this decline, suggesting that “MFN, if unchecked, risks making those trends significantly worse.” Stay tuned as NAVLIN Daily reports from the ABPI’s annual meeting today
Eli Lilly's oral weight-loss drug Foundayo (orforglipron) is set to launch in the UAE in May 2026, with supplies arriving in the first weekDr. Fatima Al Kaabi, Director-General of the Emirates Drug Establishment (EDE), described the approval as a milestone moment. “The UAE’s approval of orforglipron, being the second country in the world, is a significant step demonstrating the nation’s commitment to adopting the latest pharmaceutical innovations, particularly for people living with obesity,” she said Dr. Joseph k Joseph, Specialist in Internal Medicine, Right Health Clinics, Karama, Dubai, spoke to NAVLIN daily, said, "Some people are scared of injecting themselves even if it's once a week. So, for those with needle phobia, pills ensure better compliance, though it has to be taken daily,"
AstraZeneca CEO, Pascal Soriot has issued a stark warning over Germany’s planned healthcare cost-containment measures, saying his company may be forced to halt the launch of new medicines in the country if the proposals go ahead“It’s pure mathematics,” Soriot told Handelsblatt in an interview. “The financial impact on the business is simply too great.” This would be disastrous for German patients, he added, since many important new drugs are currently in the development and approval process, for example, treatments for cancer, metabolic diseases, and obesity. In the future, higher prices would have to be charged in Europe to support pharmaceutical innovationLast week, the Federal Minister of Health, Nina Warken, announced its draft bill, readjusting the recommendations of the Health Finance Commission’s (FKG) 66 measures to stabilize the GKV. Warken’s draft sets a rebate increase of 10.5% (instead of 14% proposed by the FKG) between January 1 and June 30, 2027, before moving into a fully dynamic adjustment mechanism from July 1, 2027
The EU’s Network of National Competent Authorities on Pricing and Reimbursement (NCAPR) has released a background paper in response to growing tensions over the U.S. Most Favoured Nation (MFN) drug pricing, warning against shifting financial burdens onto European health systems and reaffirming that “in Europe, health care is a social right”The paper notes that MFN debate is framed around two items. The first one is the perceived gap between the return on investment of pharmaceutical companies that is gained from sales in the U.S. versus the EU, a framing that has been used to argue that companies are undercompensated outside the American marketHowever, the European authorities counter that this interpretation overlooks the structural characteristics of their systems. Europe represents roughly a quarter of global pharmaceutical revenues and provides a highly attractive environment for investment and research. Although list prices are often lower, total returns remain strong, supported by universal coverage reaching 98–100% of approximately 455 million citizens, creating stable, predictable, and high-volume demand unmatched by more fragmented systems
Last week, NAVLIN Daily brought you key market access developments from across the globe. China issued its first national drug pricing guidance in more than a decade, and Germany moved closer to broad GKV cost-control reformsIn South Korea, new HIRA chief Hong Seung-kwon signaled a move toward more outcome- and value-based reimbursement, via "complete overhaul” of HTA systemMeanwhile, France’s HAS published its 2025 activity report, showing average timelines of 142 days, while higher clinical added benefit ratings (ASMR I–III) rose to 17% in 2025 from 10% in 2024
India’s Drug Consultative Committee (DCC) deliberated on strengthening regulatory oversight and enforcement against surrogate advertising of prescription-only medicines, with a specific focus on GLP-1 receptor agonists and similar drugs used for obesity and metabolic disordersThe DCC was informed of an advisory issued by CDSCO regarding the promotion and advertising of prescription-only medicines, including GLP-1 receptor agonists and similar drugs indicated for obesity and metabolic disorders, under the provisions of the Drugs and Cosmetics Act, 1940, and the Drugs Rules, 1945State and Union Territory drug controllers were asked to ensure compliance with approved use and ethical marketing of these medicines, while the IPC will regularly review adverse events, and authorities may act on major violations
China’s groundbreaking drug price guidance document triggered a spike in innovative drug company stocks, signifying its substantial support for innovation and value-based pricingThe guidance’s consolidated, clarified approach to pricing provides certainty around returns on investment and may boost China’s status in global launch sequencingDrug developers will need to invest in real-world evidence (RWE) generation earlier to continuously verify pricing, and commercial payers (who are rising in importance) will need to be impressed by well-considered value narratives
650+
+99%
<24
4,000+
24x7
99.5%
